The State of Antiangiogenic Therapy for Advanced Ovarian Cancer

I have read the CME Disclosures

This activity has been planned and implemented by Ciné-Med and the Angiogenesis Foundation. Ciné-Med is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing medical education for the health care team.

Ciné-Med designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit will be awarded to those who complete this activity according to the instructions and achieve a score of 70% or better on the post activity examination. A certificate of credit will be available for download to those who successfully complete the examination.

Date of original release: June 11, 2014
Date of expiration: June 10, 2015
CME Course Code: 2014OVARIAN

Practicing oncologists and primary care physicians in the U.S., researchers and medical students

In the United States alone, more than 22,240 new cases of ovarian cancer are estimated to have been diagnosed in 2013, and an estimated 14,230 will have died from this disease. Ovarian cancer is the ninth most common cancer among women, excluding non-melanoma skin cancers. It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Ovarian cancer accounts for about 3% of all cancers in women. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 72. Her lifetime chance of dying from ovarian cancer is about 1 in 100.

At the completion of this activity, participants should be able to:

  • Summarize the current clinical progress of targeted therapies in the management of ovarian cancer in early and late stage clinical trials.
  • Explain current clinical challenges in the management of ovarian cancer.
  • Interpret the outcome data from recent well-designed scientific and clinical studies of protocols studying new-targeted therapies.
  • Integrate side effect management into the long term management of patients with ovarian cancer.
  • Assess treatment options, efficacy data, and side effect management with members of the cancer treatment team, as well as cancer patients and their family members.


This activity is designed to address the following ABMS / IOM competencies:
Patient Care and Medical Knowledge

There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website ( in the CME section. A print version is also available; for more information contact After reviewing the material, CME credits are available through the Angiogenesis Foundation's website ( by selecting the name of the program (registration required). Course code: 2014OVARIAN

This activity is supported by educational grants from Genentech.

William Li, MD
Dartmouth Medical College

Cine-Med adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

All Cine-Med and Angiogenesis Foundation employees in control of content have indicated that they have no relevant financial relationships to disclose.

William W. Li, M.D.
President, the Angiogenesis Foundation
Disclosure: No relevant financial relationships to disclose


The State of Antiangiogenic Therapy for Advanced Ovarian Cancer:

  • The State of Antiangiogenic Therapy for Advanced Ovarian Cancer
  • Anti-VEGF Monoclonal Antibody
  • Multitargeted Antiangiogenic Agents
  • Metronomic Chemotherapy
  • Biomarkers
  • Safety of Antiangiogenic Therapy for Ovarian Cancer
  • Future Directions


This educational program is available as a mobile application and a PDF file. The mobile application can be run on any iOS or Android device. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site:

For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or